MeiraGTx Holdings PLC (MGTX) Giá

MeiraGTx Holdings Plc is a clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. The company is headquartered in New York City, New York and currently employs 409 full-time employees. The company went IPO on 2018-06-08. The company has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. The company is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.